ASCO GU 2021: Enfortumab vedotin as treatment option for bladder cancer
Interim data from a clinical trial investigating the efficacy of enfortumab vedotin (EV) on...
Read More
Meeting Coverage
ASCO GU 2021: New standard of care recommended for upper tract urothelial cancer
The Institute of Cancer Research in the UK found that the implementation of gemcitabine-platinum...
Read MoreResults from Phase 3 CLEAR Study for Advanced RRC
In patients with advanced RCC, second-line treatment with LEN + EVE prolonged progression-free survival (PFS) compared with EVE alone. LEN + PEMBRO, also showed preliminary efficacious evidence in a phase 1/2 RCC study. Here, we...
Read MoreASCO GU 2021 Kicks Off! What to Expect
The 2021 Genitourinary (GU) Cancers Symposium, one of the largest conference in genitourinary cancers will be held virtually February 11 to 13, showcasing practice-changing research, diverse speakers, global perspectives, and...
Read MorePhase 3 TITAN: Overall Survival Benefit and Safety in Advanced Prostate Cancer
Treatment with apalutamide Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer Final analysis from Phase 3 TITAN study demonstrated apalutamide provided statistically...
Read MoreASCO GU 2021: Adding to the Armamentarium of Therapy for Bladder Cancer
In high-risk muscle-invasive urothelial carcinoma, the use of nivolumab after surgery cut patients’ risk of disease returning or death by 30% over placebo. The data was released for presentation at the American Society of...
Read MoreData on Cabozantinib Activity in Brain Metastases in RCC
Results from a retrospective analysis evaluating (cabozantinib) activity in brain metastases in patients with renal cell carcinoma (RCC) will be presented as part of the Poster Session: Renal Cell Cancer at the 2021 American...
Read More
Test Your Knowledge: AHA 2020 Quiz
It’s no question that advancements in the treatment of hyperlipidemia were in the spotlight...
Read MoreConference Coverage of AAO 2020 Annual Meeting – eBook
AAO Macular Degeneration Conference Report.indd Featuring Brolucizumab forWet AMD: Assessing Profiles & Early Outcomes Cataract Surgery inWet AMD: Assessing Outcomes & Complications Assessing a Novel Contrast Sensitivity...
Read MoreUpdate on monarchE Trial: Abemaciclib Continues to Show Strong Efficacy
[flippingbook width=”100%” height=”auto” ratio=”3:2″ title=”Verzenio – MonarchE”]https://online.flippingbook.com/view/449874131/[/flippingbook] In an extended analysis of the...
Read MoreSABCS 2020: How to avoid chemotherapy overtreatment in breast cancer
Certain patients with luminal early breast cancer and up to 3 involved lymph nodes can be treated with adjuvant endocrine therapy alone, according to the primary outcome analysis of the ADAPT HR+/HER2- trial (NCT01779206),...
Read MorePhysQuiz Answers! A Focus on Allergic Asthma
Thank you for taking our quiz on allergic asthma! How did you do? 1) What percent of patients diagnosed with severe asthma (mean age of 12 years) were drug adherent, according to a study presented at AAAAI? a) 43% b) 57% c) 68%...
Read MorePhysQuiz Answers! A Focus on Chronic Idiopathic Urticaria
Thank you for taking our quiz on chronic urticaria! How did you do? 1) The NCBI recently released recommendations for diagnosis and management of chronic idiopathic urticaria, recommends using a skin prick test as part of...
Read MorePhysQuiz Answers! ASCO GU: Renal Cell Carcinoma
1) Results released from the Phase 3 CLEAR Trial found that lenvatinib combined with EITHER of these two drugs demonstrated significant benefits over sunitinib in patients with advanced RCC: a) pembrolizumab or...
Read MoreSABCS 2020: First Immunotherapy Combo Well-Tolerated
In an interim analysis of the first immunotherapy combination phase 1b trial with trastuzumab deruxtecan, safety results showed nivolumab with trastuzumab deruxtecan was well tolerated in patients with HER2-positive or HER2-low...
Read MoreSABCS 2020: Update from the DESTINY-Breast01 trial
In an updated analysis of the phase 2 DESTINY-Breast01 study, women with HER2-positive metastatic breast cancer taking antibody-drug conjugate trastuzumab deruxtecan continued to demonstrate favorable efficacy data, durable...
Read More
ACR 2020: COVID-19 Impact On DMARD Changes
Researchers conducted a study to assess the medical and clinical changes patients with rheumatoid...
Read More
ACR 2020: Delay in Transition from Psoriasis to Psoriatic Arthritis
Psoriatic arthritis (PsA) is a heterogeneous disease which may precede, occur concurrently, or...
Read More
ACR 2020: Psoriatic Arthritis And Impact of Unacceptable Symptom State
Despite numerous effective therapies for patients with psoriatic arthritis (PsA), many do not...
Read More
ACR 2020: Guselkumab in Psoriasis Patients with and Without Psoriatic Arthritis
Guselkumab (GUS), a fully human monoclonal antibody, selectively binds and blocks IL-23. VOYAGE 1...
Read More